DigiVis: Self-testing Vision App for Telephone Consultations
Primary Purpose
Visual Impairment, Amblyopia Suspect
Status
Unknown status
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
DigiVis visual acuity app
Sponsored by
About this trial
This is an interventional diagnostic trial for Visual Impairment
Eligibility Criteria
Inclusion Criteria:
- Age between 5 and 85 years
- Previous recorded visual acuity of at least +0.8 logMAR in or both eyes
Exclusion Criteria:
- Individuals with poor conversant English
- Individuals with cognitive impairment
- Subjects unable to access the internet on two digital devices
Sites / Locations
- Cambridge University Hospitals NHS TrustRecruiting
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
subjects recruited to visual acuity testing
Arm Description
All recruited subjects will have the intervention (Digivis visual acuity self-testing) and the standard clinical visual acuity assessment in clinic.
Outcomes
Primary Outcome Measures
Comparison of visual acuity measurement using DigiVis testing and standard visual acuity testing
Measurement bias in logMAR units between DigiVis testing and standard visual acuity testing score compared to
Levels of Agreement between DigiVis testing and standard visual acuity testing
Upper and lower levels of agreement measured in logMAR units
Secondary Outcome Measures
DigiVis test repeatability
Measurement of test-retest variability
Full Information
NCT ID
NCT04482387
First Posted
July 17, 2020
Last Updated
January 12, 2021
Sponsor
Cambridge University Hospitals NHS Foundation Trust
1. Study Identification
Unique Protocol Identification Number
NCT04482387
Brief Title
DigiVis: Self-testing Vision App for Telephone Consultations
Official Title
DigiVis: Validation of Self-testing Visual Acuity Web-based App to Aid Ophthalmic Telephone Consultations During Covid19 Lockdown and Subsequent Social Distancing Crisis
Study Type
Interventional
2. Study Status
Record Verification Date
January 2021
Overall Recruitment Status
Unknown status
Study Start Date
July 24, 2020 (Actual)
Primary Completion Date
July 1, 2021 (Anticipated)
Study Completion Date
July 1, 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Cambridge University Hospitals NHS Foundation Trust
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This trial aims to assess the accuracy and test-retest variability of a new digital app which enables community visual acuity testing without requirement of an trained examiner.
Detailed Description
Eye problems like macular degeneration and amblyopia (lazy eye) require regular monitoring to prevent permanent visual impairment. Over 2000 patients a month are seen in Cambridge University Hospitals NHS Trust (CUH) eye clinics; concern about Covid-19 infection has led to over 80% of consultations being conducted by telephone with few clinical clues to inform decision making. Patients will face long delays even when routine clinics restart: there is no doubt that some will suffer preventable visual loss.
DigiVis is a web-based vision testing app enabling self-testing of vision at home. Early testing and patient feedback is positive: 80% of children prefer DigiVis to regular testing. The investigators wish to test how accurately the app works for home use, by asking older children and adults to self-test their vision prior to their planned face to face clinic appointment. Once tested, DigiVis will be available free of charge to patients, not only during the Covid-19 crisis, but also to support telephonic consultations in the future.
Visual acuity (VA) is a fundamental measure of vision required for all ophthalmic assessments. It is measured by health professionals using vision charts. DigiVis is a new app which enables self-testing of VA using two wirelessly connected digital devices. By matching letters on a handheld device to those displayed on the second device a distance away, threshold VA can be measured using a staircase algorithm. The distance and scaling of the test is vital to its accuracy and a concept (patent filed by Cambridge Enterprise) in DigiVis enables this without the need for manual distance measurement or an observer.
Early validation using two tablet computers in 150 clinic patients has given positive results, both in testing accuracy and patient feedback. With the current Covid-19 crisis limiting face to face appointments, there is an urgent need for accurate home VA assessment. The DigiVis app has been re-coded for free website delivery for this purpose.
The investigators wish to formally validate DigiVis home testing following Conformitè Europëenne (CE class I) marking so that it can be recommended for clinical use. 250 patients will be invited to self-test their VA twice using DigiVis prior to a planned face to face clinic appointment. The test-retest variability and comparison of DigiVis VA to chart based assessment will be compared.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Visual Impairment, Amblyopia Suspect
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Model Description
Patients will test their own vision twice using the DigiVis app twice, subsequently they will have visual acuity assessment in eye clinic by a trained examiner. The results of visual acuity will be compared using Bland Altman statistical analysis.
Masking
None (Open Label)
Masking Description
The eye clinic visual acuity examiner will be masked to the result of the DigiVis tests.
Allocation
N/A
Enrollment
250 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
subjects recruited to visual acuity testing
Arm Type
Other
Arm Description
All recruited subjects will have the intervention (Digivis visual acuity self-testing) and the standard clinical visual acuity assessment in clinic.
Intervention Type
Device
Intervention Name(s)
DigiVis visual acuity app
Intervention Description
Self-testing of visual acuity app on two occasions
Primary Outcome Measure Information:
Title
Comparison of visual acuity measurement using DigiVis testing and standard visual acuity testing
Description
Measurement bias in logMAR units between DigiVis testing and standard visual acuity testing score compared to
Time Frame
within 30 days
Title
Levels of Agreement between DigiVis testing and standard visual acuity testing
Description
Upper and lower levels of agreement measured in logMAR units
Time Frame
within 30 days
Secondary Outcome Measure Information:
Title
DigiVis test repeatability
Description
Measurement of test-retest variability
Time Frame
within 30 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Age between 5 and 85 years
Previous recorded visual acuity of at least +0.8 logMAR in or both eyes
Exclusion Criteria:
Individuals with poor conversant English
Individuals with cognitive impairment
Subjects unable to access the internet on two digital devices
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Louise E Allen, MBBS MD
Phone
07941666981
Email
louise@louiseallen.com
First Name & Middle Initial & Last Name or Official Title & Degree
Nabil Uddin
Email
nabil.uddin@addenbrookes.nhs.uk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stephen E Kelleher
Organizational Affiliation
Cambridge University Hospitals NHS Foundation Trust
Official's Role
Study Director
Facility Information:
Facility Name
Cambridge University Hospitals NHS Trust
City
Cambridge
State/Province
Cambs
ZIP/Postal Code
CB2 0QQ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Louise Allen
Phone
07941666981
Email
louise@louiseallen.com
First Name & Middle Initial & Last Name & Degree
Nabil Uddin
Email
nabil.uddin@addenbrookes.nhs.uk
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
30012273
Citation
Rono HK, Bastawrous A, Macleod D, Wanjala E, Di Tanna GL, Weiss HA, Burton MJ. Smartphone-based screening for visual impairment in Kenyan school children: a cluster randomised controlled trial. Lancet Glob Health. 2018 Aug;6(8):e924-e932. doi: 10.1016/S2214-109X(18)30244-4. Erratum In: Lancet Glob Health. 2018 Oct;6(10):e1072.
Results Reference
background
PubMed Identifier
26022921
Citation
Bastawrous A, Rono HK, Livingstone IA, Weiss HA, Jordan S, Kuper H, Burton MJ. Development and Validation of a Smartphone-Based Visual Acuity Test (Peek Acuity) for Clinical Practice and Community-Based Fieldwork. JAMA Ophthalmol. 2015 Aug;133(8):930-7. doi: 10.1001/jamaophthalmol.2015.1468. Erratum In: JAMA Ophthalmol. 2015 Sep;133(9):1096.
Results Reference
background
Learn more about this trial
DigiVis: Self-testing Vision App for Telephone Consultations
We'll reach out to this number within 24 hrs